Resources from the same session
The predictive value of the CA-125 modeled kinetic parameter KELIM is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)
Presenter: Benoit MP You
Session: Gynaecological cancers
Resources:
Abstract
The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome
Presenter: Gwénaël Ferron
Session: Gynaecological cancers
Resources:
Abstract
Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers
Presenter: Ignace Vergote
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052)
Presenter: Susana Banerjee
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
Invited discussant abstracts 859PD, 860PD and LBA35
Presenter: Ignace Vergote
Session: Gynaecological cancers
Resources:
Presentation
Webcast
Invited discussant abstract 856O and LBA33
Presenter: Domenica Lorusso
Session: Gynaecological cancers
Resources:
Presentation
Webcast
Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial
Presenter: Roman Rouzier
Session: Gynaecological cancers
Resources:
Abstract
Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)
Presenter: Rebecca Kristeleit
Session: Gynaecological cancers
Resources:
Abstract
Presentation
Webcast
A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)
Presenter: Jung-Min Lee
Session: Gynaecological cancers
Resources:
Abstract
A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)
Presenter: Jasgit Sachdev
Session: Gynaecological cancers
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.